| Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective HM Jones, Y Chen, C Gibson, T Heimbach, N Parrott, SA Peters, ... Clinical Pharmacology & Therapeutics 97 (3), 247-262, 2015 | 456 | 2015 |
| Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective M Shebley, P Sandhu, A Emami Riedmaier, M Jamei, R Narayanan, ... Clinical Pharmacology & Therapeutics 104 (1), 88-110, 2018 | 294 | 2018 |
| Physiologically based pharmacokinetic (PBPK) modeling and simulations: principles, methods, and applications in the pharmaceutical industry SA Peters John Wiley & Sons, 2021 | 251 | 2021 |
| Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis SA Peters Clinical pharmacokinetics 47, 261-275, 2008 | 150 | 2008 |
| Predicting drug extraction in the human gut wall: assessing contributions from drug metabolizing enzymes and transporter proteins using preclinical models SA Peters, CR Jones, AL Ungell, OJD Hatley Clinical pharmacokinetics 55, 673-696, 2016 | 102 | 2016 |
| Physiologically‐based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective T Heimbach, Y Chen, J Chen, V Dixit, N Parrott, SA Peters, I Poggesi, ... Clinical Pharmacology & Therapeutics 110 (2), 297-310, 2021 | 70 | 2021 |
| Gut wall metabolism. Application of pre-clinical models for the prediction of human drug absorption and first-pass elimination CR Jones, OJD Hatley, AL Ungell, C Hilgendorf, SA Peters, ... The AAPS journal 18, 589-604, 2016 | 69 | 2016 |
| Model-based drug discovery: implementation and impact SAG Visser, M Aurell, RDO Jones, VJA Schuck, AC Egnell, SA Peters, ... Drug discovery today 18 (15-16), 764-775, 2013 | 62 | 2013 |
| Requirements to establishing confidence in physiologically based pharmacokinetic (PBPK) models and overcoming some of the challenges to meeting them SA Peters, H Dolgos Clinical pharmacokinetics 58 (11), 1355-1371, 2019 | 54 | 2019 |
| Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles SA Peters Clinical pharmacokinetics 47, 245-259, 2008 | 53 | 2008 |
| Evaluating the role of solubility in oral absorption of poorly water‐soluble drugs using physiologically‐based pharmacokinetic modeling C Fink, D Sun, K Wagner, M Schneider, H Bauer, H Dolgos, K Mäder, ... Clinical Pharmacology & Therapeutics 107 (3), 650-661, 2020 | 49 | 2020 |
| Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development FH Karlsson, S Bouchene, C Hilgendorf, H Dolgos, SA Peters Drug Metabolism and Disposition 41 (12), 2033-2046, 2013 | 47 | 2013 |
| Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development SA Peters, PE Schroeder, N Giri, H Dolgos Drug Metabolism and Disposition 40 (8), 1495-1507, 2012 | 46 | 2012 |
| Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat SA Peters, L Hultin Journal of pharmacokinetics and pharmacodynamics 35, 1-30, 2008 | 41 | 2008 |
| Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization SA Peters, AL Ungell, H Dolgos Curr Opin Drug Discov Devel 12 (4), 509-518, 2009 | 35 | 2009 |
| Recommendations for the design of clinical drug–drug interaction studies with itraconazole using a mechanistic physiologically‐based pharmacokinetic model Y Chen, TD Cabalu, E Callegari, H Einolf, L Liu, N Parrott, SA Peters, ... CPT: Pharmacometrics & Systems Pharmacology 8 (9), 685-695, 2019 | 32 | 2019 |
| A comparative evaluation of models to predict human intestinal metabolism from nonclinical data E Yau, C Petersson, H Dolgos, SA Peters Biopharmaceutics & drug disposition 38 (3), 163-186, 2017 | 31 | 2017 |
| A retrospective evaluation of allometry, population pharmacokinetics, and physiologically‐based pharmacokinetics for pediatric dosing using clearance as a surrogate Q Wu, SA Peters CPT: pharmacometrics & systems pharmacology 8 (4), 220-229, 2019 | 29 | 2019 |
| Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity P Gardiner, C Wikell, S Clifton, J Shearer, A Benjamin, SA Peters British Journal of Pharmacology 173 (15), 2390-2401, 2016 | 23 | 2016 |
| Impact of input parameters on the prediction of hepatic plasma clearance using the well-stirred model H Wan, P Bold, LO Larsson, J Ulander, S Peters, B Lofberg, AL Ungell, ... Current drug metabolism 11 (7), 583-594, 2010 | 23 | 2010 |
Neil ParrottModeling and simulation scientist, F. Hoffmann-LaRocheVerified email at roche.com
